Aquestive Therapeutics (AQST) Current Assets (2017 - 2026)

Aquestive Therapeutics' Current Assets history runs 10 years deep, the most recent figure standing at $130.2 million for Q1 2026.

• In Q1 2026, Current Assets rose 46.0% year-over-year to $130.2 million; the TTM figure through Mar 2026 stood at $130.2 million (up 46.0% YoY), while the FY2025 annual figure was $149.3 million, up 69.2% from the prior year.
• Current Assets was $130.2 million for Q1 2026 at Aquestive Therapeutics, down from $149.3 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $151.7 million in Q3 2025 to a low of $38.1 million in Q3 2022.
• Historically, Current Assets has averaged $78.5 million across 5 years, with a median of $81.7 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Current Assets decreased 24.14% in 2022, then jumped 161.41% in 2024.
• A 5-year view of Current Assets shows it stood at $39.9 million in 2022, then increased by 2.7% to $41.0 million in 2023, then jumped by 115.35% to $88.2 million in 2024, then surged by 69.2% to $149.3 million in 2025, then fell by 12.79% to $130.2 million in 2026.
• The last three Current Assets figures came in at $130.2 million (Q1 2026), $149.3 million (Q4 2025), and $151.7 million (Q3 2025), per Business Quant data.